Pfizer Inc (PFE)

31.77
NYSE : Health Care
Prev Close 31.70
Day Low/High 31.66 / 32.12
52 Wk Low/High 28.25 / 37.39
Avg Volume 28.01M
Exchange NYSE
Shares Outstanding 6.07B
Market Cap 192.37B
EPS 1.10
P/E Ratio 15.17
Div & Yield 1.28 (4.00%)

Latest News

There May Be a Buying Opportunity When Pfizer Shares Hit This Important Level

There May Be a Buying Opportunity When Pfizer Shares Hit This Important Level

Shares of Pfizer have been on the decline, losing some 5% from its January 5 high of $33.61 a share.

Eli Lilly Acquires CoLucid Pharma, Adds Migraine Drug to Pipeline

Eli Lilly Acquires CoLucid Pharma, Adds Migraine Drug to Pipeline

CoLucid will be acquired for $46.50 per share, a 33% premium to the stock's closing price Tuesday.

Why Bristol-Myers Squibb May Be a Merger Target Soon

Why Bristol-Myers Squibb May Be a Merger Target Soon

The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.

Versartis' Pipeline Holds Big Promise

Versartis' Pipeline Holds Big Promise

This small-cap biotech name could have further to run.

Versartis' Pipeline Holds Big Promise

Versartis' Pipeline Holds Big Promise

This small-cap biotech name could have further to run.

Could Johnson & Johnson Rip Higher by 20%?

Could Johnson & Johnson Rip Higher by 20%?

It may just happen. Here is why.

An All-Inclusive Portfolio Update

Earnings previews, company updates, dividend reminders -- the works.

Cramer: Trump Doesn't Seem to Care About the Trump Rally

Cramer: Trump Doesn't Seem to Care About the Trump Rally

He's never really been a stock market guy anyway.

Trump Tax Policies Could Make J&J a Bigger Threat in 2017

Trump Tax Policies Could Make J&J a Bigger Threat in 2017

While there remains many unknowns about the specifics of possible legislation, CEO Alex Gorsky suggested that tax reform and repatriation could be a major game changer for J&J.

Celebrate One Debacle of a Merger With Another -- ICYMI

Celebrate One Debacle of a Merger With Another -- ICYMI

America Online and Time Warner see the 17-year anniversary of their combination come and go, as both companies are involved in separate merger dramas today.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Cramer: How Walmart, Amex, IBM and Nike Could Help the Dow Hit 20,000

Cramer: How Walmart, Amex, IBM and Nike Could Help the Dow Hit 20,000

These four Dow components (and eight others I'm watching) are nowhere near record highs.

Technology Rules as Only S&P Sector Hitting a New High

Technology Rules as Only S&P Sector Hitting a New High

Of the 11 S&P 500 sectors, technology leads followed by gain from health care and consumer discretionary stocks. Here's how you trade these sectors using exchange-traded funds.

Cramer: A Dozen Stocks in the Dow That Can Regain Their Former Glory

Cramer: A Dozen Stocks in the Dow That Can Regain Their Former Glory

You have to think that if these stocks were so high once, then it's likely they will be again.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Too Few Stocks Doing Too Much: Jim Cramer's Best Blog

Too Few Stocks Doing Too Much: Jim Cramer's Best Blog

Jim Cramer ponders how too few stocks are doing too much in the Dow's race to 20,000 and how there isn't enough GANG to go with all the FANG.

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Jim Cramer says he's focusing on health-care companies that will break news that moves stocks.

Cramer: Too Few Stocks Are Doing Too Much in Dow's Run to 20,000

Cramer: Too Few Stocks Are Doing Too Much in Dow's Run to 20,000

Disney and Goldman are doing a lot of the heavy lifting.

ICU Medical Wins Big Price Cut to Buy Pfizer's Hospira Unit

ICU Medical Wins Big Price Cut to Buy Pfizer's Hospira Unit

ICU Medical will pay $900 million for the infusion therapy unit rather than $1 billion.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Pfizer Unveils Positive Results from Study of Potential Humira Biosimilar

Pfizer Unveils Positive Results from Study of Potential Humira Biosimilar

Thursday's announcement marks Pfizer's third proposed biosimilar pipeline molecule to announce positive top-line results within the past four months.

Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio

Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio

Congressional Republicans who scrapped plans to overhaul the Office of Congressional Ethics might be regretting their decision. Senate Dems are asking for an investigation into HHS pick Tom Price.

What Pharma and Health Care Investors Should Watch for at JPM

What Pharma and Health Care Investors Should Watch for at JPM

The largest investor conference for the health care industry kicks off on Monday in San Francisco.

Pfizer Announces Positive Top-Line Results From The Comparative REFLECTIONS B538-02 Study For PF-06410293, A Potential Biosimilar To Humira®1 (adalimumab)

Pfizer Announces Positive Top-Line Results From The Comparative REFLECTIONS B538-02 Study For PF-06410293, A Potential Biosimilar To Humira®1 (adalimumab)

Pfizer Inc. (NYSE:PFE) today announced that the comparative, confirmatory REFLECTIONS B538-02 study met its primary objective by demonstrating equivalent efficacy as measured by the American College of Rheumatology 20...

Here's When to Buy Chevron, IBM, 3 More High-Yielding Dow 'Dogs'

Here's When to Buy Chevron, IBM, 3 More High-Yielding Dow 'Dogs'

Chevron, Pfizer, IBM, Caterpillar and Coca-Cola are showing breakout technical charts.

What Did Dow's 'Dogs' Fetch in 2016?

What Did Dow's 'Dogs' Fetch in 2016?

None of these 10 stocks finished the year in the red.